Jmir Cancer
Overview
Jmir Cancer is a scientific journal, published by JMIR Publications since 2015 in English. The journal's country of origin is Canada and its primary focus area is oncology.
Details
Details
Abbr.
JMIR Cancer
Publisher
JMIR Publications
Start
2015
End
Continuing
Frequency
Semiannual
e-ISSN
2369-1999
Country
Canada
Language
English
Specialty
Oncology
Metrics
Metrics
h-index / Ranks: 11552
24
SJR / Ranks: 5368
790
CiteScore / Ranks: 7633
3.50
Recent Articles
11.
Tang W, Mo S, Xie Y, Wei T, Chen G, Teng Y, et al.
JMIR Cancer
. 2025 Mar;
11:e54625.
PMID: 40036657
Background: Male breast cancer (MBC) is an uncommon disease. Few studies have discussed the prognosis of MBC due to its rarity. Objective: This study aimed to develop a nomogram to...
12.
Werts-Pelter S, Chen Z, Bea J, Sokan A, Thomson C
JMIR Cancer
. 2025 Mar;
11:e66636.
PMID: 40036646
Background: Though telehealth has been a promising avenue for engaging cancer survivors with health care and lifestyle programming, older and rural-dwelling cancer survivors may have additional challenges in accessing digital...
13.
Takahashi N, Nakao M, Nakayama T, Yamazaki T
JMIR Cancer
. 2025 Mar;
11:e64020.
PMID: 40036529
Background: Breast cancer is a major health concern in various countries. Routine mammography screening has been shown to reduce breast cancer mortality, and Japan has set national targets to improve...
14.
Sommers J, Dizon D, Lewis M, Stone E, Andreoli R, Henderson V
JMIR Cancer
. 2025 Mar;
11:e56098.
PMID: 40029972
Background: The lack of information and awareness about clinical trials, as well as misconceptions about them, are major barriers to cancer clinical trial participation. Digital and social media are dominant...
15.
Aye P, Barnes J, Laking G, Cameron L, Anderson M, Luey B, et al.
JMIR Cancer
. 2025 Mar;
11:e65118.
PMID: 40029742
Background: Health care system-wide outcomes from routine treatment with erlotinib and gefitinib are incompletely understood. Objective: The aim of the study is to describe the effectiveness of erlotinib and gefitinib...
16.
Leveraging Patient-Reported Outcome Measures for Optimal Dose Selection in Early Phase Cancer Trials
Byrom B, Everhart A, Cordero P, Garratt C, Meyer T
JMIR Cancer
. 2025 Feb;
11:e64611.
PMID: 40020239
While patient-reported outcome measures are regularly incorporated into phase 3 clinical trials, they have been infrequently used in early phase trials. However, the patient's perspective is vital to fully understanding...
17.
Newton L, Monkman H, Fullerton C
JMIR Cancer
. 2025 Feb;
11:e59391.
PMID: 40014827
Background: Older adults (aged >65 years) are disproportionately affected by cancer at a time when Canadians are surviving cancer in an unprecedented fashion. Contrary to persistent ageist assumptions, not only...
18.
Dabbagh Z, Najjar R, Kamberi A, Gerber B, Singh A, Soni A, et al.
JMIR Cancer
. 2025 Feb;
11:e60034.
PMID: 39993013
Background: Despite the known benefits of physical activity, cancer survivors remain insufficiently active. Prior trials have adopted digital health methods, although several have been pedometer-based and enrolled mainly female, non-Hispanic...
19.
Yang H, Zhu C, Zhou C, Huang R, Huang L, Chen P, et al.
JMIR Cancer
. 2025 Feb;
11:e59483.
PMID: 39970367
Background: Breast cancer is the most common malignant tumor and the fifth leading cause of cancer death worldwide, imposing a significant disease burden in China. Mammography is a key method...
20.
Chow J, Li K
JMIR Cancer
. 2025 Feb;
11:e66633.
PMID: 39965195
This Viewpoint proposes a robust framework for developing a medical chatbot dedicated to radiotherapy education, emphasizing accuracy, reliability, privacy, ethics, and future innovations. By analyzing existing research, the framework evaluates...